biostudies-literatureGreenstein YYNHLBI NIH HHSNational Heart, Lung, and Blood InstituteNational Institutes of HealthNIH785-799https://www.ebi.ac.uk/biostudies/studies/S-EPMC11026170biostudies-literatureUnknown165(4)<h4>Background</h4>Therapeutic-dose heparin decreased days requiring organ support in noncritically ill patients hospitalized for COVID-19, but its impact on persistent symptoms or quality of life (QOL) is unclear.<h4>Research question</h4>In the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4a) trial, was randomization of patients hospitalized for COVID-19 illness to therapeutic-dose vs prophylactic heparin associated with fewer symptoms and better QOL at 90 days?<h4>Study design and methods</h4>This was an open-label randomized controlled trial at 34 hospitals in the United States and Spain. A total of 727 noncritically ill patients hospitalized for COVID-19 from September 2020 to June 2021 were randomized to therapeutic-dose vs prophylactic heparin. Only paChestSymptoms and Impaired Quality of Life After COVID-19 Hospitalization: Effect of Therapeutic Heparin in Non-ICU Patients in the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 Acute Trial: Effect on 3-Month Symptoms and Quality of Life.PMC110261701OT2HL156812-01OT2 HL156812OTA-20-011Colovos CFroess JChang SYShah FGaddh MLai YHBerger JSGuerrero RMVenugopal VWisniewski SRHuang DTGoligher ECNkemdirim WLopes RDHubel KLawler PRKornblith LZLeifer EGreenstein YYHochman JSGong MNCushman MWahid LZahra AZarychanski RAmigo JSNeal MDReynolds HRfalseSymptoms and Impaired Quality of Life After COVID-19 Hospitalization: Effect of Therapeutic Heparin in Non-ICU Patients in the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 Acute Trial: Effect on 3-Month Symptoms and Quality of Life.<h4>Background</h4>Therapeutic-dose heparin decreased days requiring organ support in noncritically ill patients hospitalized for COVID-19, but its impact on persistent symptoms or quality of life (QOL) is unclear.<h4>Research question</h4>In the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4a) trial, was randomization of patients hospitalized for COVID-19 illness to therapeutic-dose vs prophylactic heparin associated with fewer symptoms and better QOL at 90 days?<h4>Study design and methods</h4>This was an open-label randomized controlled trial at 34 hospitals in the United States and Spain. A total of 727 noncritically ill patients hospitalized for COVID-19 from September 2020 to June 2021 were randomized to therapeutic-dose vs prophylactic heparin. Only pa2024-01-01T00:00:00Z2024 Apr2026-06-01T07:45:46.832Z2025-07-04T03:05:45.627ZS-EPMC110261703797971710.1016/j.chest.2023.11.019